LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Neurocrine Biosciences Inc

Closed

SectorHealthcare

120.9 0.52

Overview

Share price change

24h

Current

Min

118.17

Max

121.26

Key metrics

By Trading Economics

Income

-95M

7.9M

Sales

-55M

573M

P/E

Sector Avg

40.824

56.602

EPS

0.7

Profit margin

1.38

Employees

1,800

EBITDA

-146M

24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+34.8% upside

Dividends

By Dow Jones

Next Earnings

31 Jul 2025

Market Stats

By TradingEconomics

Market Cap

289M

12B

Previous open

120.38

Previous close

120.9

News Sentiment

By Acuity

17%

83%

24 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Neurocrine Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Jan 2025, 00:03 UTC

Hot Stocks

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14 Mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

13 Aug 2024, 11:30 UTC

Top News

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Peer Comparison

Price change

Neurocrine Biosciences Inc Forecast

Price Target

By TipRanks

34.8% upside

12 Months Forecast

Average 160.11 USD  34.8%

High 192 USD

Low 115 USD

Based on 21 Wall Street analysts offering 12 month price targets forNeurocrine Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

20

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

109.55 / 121.61Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

24 / 382 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.